Geeta Vemuri

Geeta Vemuri joined Baxter in January, 2012 as VP, Head of Baxter Ventures, the corporation's $200 million venture fund. Prior to joining Baxter, she was a General Partner at Quaker Partners, where she spent her time leading investments in Biopharmaceutical and Healthcare companies and being integral part of the team in raising capital for the funds. Dr. Vemuri's role in building and mentoring portfolio companies has helped lead their exit through either acquisition or through Initial Public Offering. Some of her representative Quaker portfolio board member or observer responsibilities include Protez, Cempra, Corridor, Regado and Tranzyme Pharma. Prior to Quaker, she was an Associate at Toucan Capital, where she was responsible for investments in seed-stage and start-up biotech opportunities. She participated in raising capital and helped start portfolio companies by identifying technologies from universities. Prior to that, she was an Associate Equity Analyst at SalomonSmithBarney and First Union Securities covering specialty pharmaceuticals and healthcare sectors. Geeta was also a research scientist at The Wistar Institute and completed her postdoctoral fellow program at Thomas Jefferson University. Dr. Vemuri received her M.S. from Central University in India, her Ph.D. in biochemistry from the Indian Institute of Sciences, and her M.B.A. from the Wharton School of the University of Pennsylvania.